NuVasive (Nasdaq: NUVA) reported earnings on July 30. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), NuVasive beat expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue increased. Non-GAAP earnings per share dropped significantly. GAAP earnings per share contracted to a loss.

Margins dropped across the board.

Revenue details
 NuVasive logged revenue of $165.7 million. The 21 analysts polled by S&P Capital IQ predicted a top line of $161.7 million on the same basis. GAAP reported sales were 7.3% higher than the prior-year quarter's $154.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.20. The 20 earnings estimates compiled by S&P Capital IQ averaged $0.24 per share. Non-GAAP EPS of $0.20 for Q2 were 26% lower than the prior-year quarter's $0.27 per share. GAAP EPS were -$0.15 for Q2 versus $0.06 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 70.6%, 570 basis points worse than the prior-year quarter. Operating margin was 0.0%, 840 basis points worse than the prior-year quarter. Net margin was -3.9%, 580 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $158.8 million. On the bottom line, the average EPS estimate is $0.24.

Next year's average estimate for revenue is $656.3 million. The average EPS estimate is $1.01.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 171 members out of 189 rating the stock outperform, and 18 members rating it underperform. Among 40 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give NuVasive a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $23.38.

Is NuVasive the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.